Navigation Links
ReachBio Launches HemoRANK-TKI Service Package for Predicting Myelotoxicity of New Tyrosine Kinase Inhibitors
Date:9/15/2009

SEATTLE, Sept. 15 /PRNewswire/ -- ReachBio LLC announced today the launch of HemoRANK(TM)-TKI, an in vitro assay service package that helps predict the potential of novel therapeutic tyrosine kinase inhibitors (TKIs) to cause clinical hematotoxicity (myelotoxicity or neutropenia). This assay system is designed to help biotechnology and pharmaceutical companies that are developing novel therapeutic TKIs gain insight into the likelihood and degree to which their compounds might cause neutropenia in patients and thus aid in lead candidate selection, structure-toxicity relationship research, and other areas of non-clinical and investigative toxicology research.

(Logo:http://www.newscom.com/cgi-bin/prnh/20080226/REACHBIOLOGO)

The HemoRANK(TM)-TKI contract assay service package is a standardized test system in which one or more novel TKIs are run in robust in vitro human bone marrow progenitor assays (CFU-GM assays) in parallel with a standard panel of up to 6 TKIs that are currently approved for therapeutic use. The TKIs available for the standard panel (Lapatinib, Erlotinib, Sorafenib, Imatinib, Sunitinib and Dasatinib) have known different levels of clinical myelotoxicity, as reported in the medical literature. The rank order of in vitro IC(50) values for these compounds obtained by the HemoRANK(TM) system correlates with the degree to which they cause neutropenia in the clinic. Novel compounds tested within the system are ranked against the standard panel and informed predictions can then be made regarding the likely level of clinical neutropenia they will cause. Testing against a reduced panel of the client's choosing or against blinded or unblinded controls provided directly by the client is also an option.

According to Dr. Emer Clarke, Chief Scientific Officer for ReachBio, "we have found that in our hands, the in vitro human CFU-GM assay is both very reproducible and highly predictive of clinical myelotoxicity for a variety of different compound classes, including kinase inhibitors. Specifically for the marketed TKIs that we tested during the development of the HemoRANK-TKI service package, the rank order of the in vitro IC(50) values that we generated correlated extremely well with the degree that these compounds have been reported to cause clinical myelotoxicity - with an R(2) value of 0.81. We believe that this type of correlation between the in vitro and clinical findings allows the system to be used to rank the myelotoxic potential of novel TKIs against the members of the same drug class that are currently on the market and to therefore predict the potential incidence, degree and severity of clinical neutropenia that the novel compounds might be expected to cause."

Dr. Eric Atkinson, president of BroadReach BioSystems and strategic advisor to ReachBio, added: "There's often a balance between drug toxicity and efficacy, and the tipping point can shift, depending upon the disease indication. As a drug class, TKIs are known to have significant myelotoxic liabilities. However, these drugs are currently being used to treat patients with certain types of cancer, and when life-threatening diseases like that are being treated, a certain degree of drug-induced neutropenia is going to be acceptable - although it's definitely an advantage to have as low a myelotoxic potential as possible even for oncology indications, since significant myelotoxicity will be dose-limiting. An emerging issue in the TKI space, however, is that these compounds have a lot of potential to be used in inflammation and other immune system diseases. The life-threatening potential of these types of diseases is generally lower than that of cancer, so the risk/benefit equation changes and the bar for an acceptable degree of toxicity will be higher. There will therefore be more and more pressure on companies developing TKIs for non-oncology applications to come up with compounds with lower levels of myelotoxicity. Being able to accurately predict the myelotoxic potential of new TKIs and especially being able to rank the potential clinical neutropenia in relation to the degree of neutropenia already established for marketed drugs of the same class, such as ReachBio's new HemoRANK-TKI test offers, is going to be extremely useful during the development of new TKIs for both oncology and non-oncology indications."

About ReachBio

ReachBio LLC is a boutique life sciences organization based in Seattle, WA. It provides specialized contract assays, contract research, educational and consulting services to pharmaceutical, biotechnology, agrichemical, and related organizations worldwide. The company's focus is on the clinical, industrial and research uses of primary cell biology - in particular the use of stem cell and progenitor cell assays and model systems for high value applications such as drug screening and drug discovery.

www.reachbio.com


'/>"/>
SOURCE ReachBio LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ReachBio Partners with Axiogenesis to Distribute Novel Cell-Based Products in North America
2. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
3. Novozymes Launches Enzyme to Reduce Acrylamide in Food
4. Enova Medical Launches Exos Corporation
5. Elekta Launches New Linear Accelerator at 2007 ESTRO to Expand Cancer Treatment Availability
6. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
7. ThirdBiotech Networking Group Launches
8. BioReliance Launches Next-Generation Genotoxicity Screening Service
9. Midwest Research Institute Launches Center for Biological Safety and Security (CBS2)
10. BioReliance Corporation Launches iNet(TM) for Online Results Tracking of Biological Safety Tests
11. Kingfisher Healthcare Launches Breakthrough Product in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the ... major shareholders, Clean Technology Fund I, LP and Clean ... based venture capital funds which together hold approximately ... fully diluted, as converted basis), that they have entered ... equity holdings in Biorem to TUS Holdings Co. Ltd. ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... innovative medical technologies, services and solutions to the healthcare market. The company's primary ... various distribution, manufacturing, sales and marketing strategies that are necessary to help companies ...
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
Breaking Biology Technology:
(Date:6/1/2016)... 2016 Favorable Government Initiatives Coupled ... Criminal Identification to Boost Global Biometrics System Market Through ... Research report, " Global Biometrics Market By Type, ... Opportunities, 2011 - 2021", the global biometrics market is ... account of growing security concerns across various end use ...
(Date:5/12/2016)... -- WearablesResearch.com , a brand of Troubadour Research ... the Q1 wave of its quarterly wearables survey. A ... to a program where they would receive discounts for ... "We were surprised to see that so ... , CEO of Troubadour Research, "primarily because there are ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):